Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Vaxil Bio Ltd V.VXL

Alternate Symbol(s):  VXLLF

Vaxil Bio Ltd. is a Canada-based biotechnology company. The Company is focused on a drug discovery and development platform based on Signal Peptides (SPs) which the Company deploys to fight infectious diseases and cancer. The Company’s most advanced product, ImMucin, a MUC1 SP-derived vaccine, completed a Phase I/II clinical trial in multiple myeloma. The Company also has a SP-based COVID-19 vaccine candidate and a SP-based tuberculosis vaccine / treatment candidate. In addition, The Company has mAb candidates for the treatment of oncology and infectious diseases to be used alone, and in combination with other treatments. It has also initiated a pre-clinical program for a drug delivery polymer that targets high affinity E-selectin (P-Esbp), which the Company licensed for development and commercialization from BGN Technologies. It exploits the properties of SP domains on crucial proteins to develop targeted therapies against cancer targets and infectious disease pathogens.


TSXV:VXL - Post by User

Comment by silentrunningon Jun 29, 2020 2:28pm
82 Views
Post# 31204245

RE:Interesting Communication....What Funding and Justify Low PP

RE:Interesting Communication....What Funding and Justify Low PPThis appears to be the standard response to pretty much any question asked to David which I can understand. However, I've spoken to a good many CEO's etc all over the world, many "seasoned" CEO's prefer the telephone rather than email for obvious reasons but still maintaining all the legal responsibilities. This CEO is a tough read...I don't get it. Maybe time to call others involved? Hospital? Lab? Been known to get closer to answers, also got the *fastest* phone call from a CEO in my life. LOL Fingers & toes crossed on peptide vaccine!
Valuehunter72 wrote:

Here is a copy of a post from the other board from May 28th at 11:50.

It is an email communication sent to David from poster Freedom40 the evening after the PP was announced.  


Notice David questions assumption/ source of funding.....meanwhile we know Lester and David had been working on Strategic Innovation Fund weeks prior.  wonder why he questioned that?

Notice he also justifies the low PP pricing by saying the stock was only 2.5 cents not long ago....

So recap....what funding you talking about man?  Yeah the 8.5 cents is justified.

Nice.....real nice.



Here is some history of communication as a reference, oldest to newest - he just responded now even though the email states otherwise: Sent: Tuesday, May 26, 2020 7:41 PM To: david@vaxil-bio.com Subject: Re: Update Hi David, Thought I would touch base after today's news, to be upfront and honest very disappointing. I had assumed along with the majority of shareholders that potential funding/partnership was incoming; clearly the need for a private placement at 0.085 speaks that is not the case. I understands the need for capital, that said without any continued update on the pre-clinical work this news is not well received by the markets, stock down 15%. If the market simply knew what Vaxil was up too perhaps it would relive some pressure and gain investor confidence back. We can only assume at this stage that the lack of updates means you are on track. I do hope that is the case. Thanks for listening. From: David Goren (VXL) Sent: May 27, 2020 12:29 AM

To: Subject: RE: Update Your comments are noted – not sure what is the source of the “assumption” of funding. In general, stock price reflects long term trends – ours was also 2.5c not long ago. When we have updates, we will issue press releases to share with everyone at the same time. Thanks David Sent: Thursday, May 28, 2020 6:32 PM To: david@vaxil-bio.com Subject: Re: Update David,



<< Previous
Bullboard Posts
Next >>